Yang J-H, Hayano M, Griffin PT, Amorim JA, Bonkowski MS, Apostolides JK, Salfati EL, Blanchette M, Munding EM, Bhakta M, Chew YC, Guo W, Yang X, Maybury-Lewis S, Tian X, Ross JM, Coppotelli G, Meer MV, Rogers-Hammond R, Vera DL, Lu YR, Pippin JW, Creswell ML, Dou Z, Xu C, Mitchell SJ, Das A, OConnell BL, Thakur S, Kane AE, Su Q, Mohri Y, Nishimura EK, Schaevitz L, Garg N, Balta A-M, Rego MA, Gregory-Ksander M, Jakobs TC, Zhong L, Wakimoto H, Andari JE, Grimm D, Mostoslavsky R, Wagers AJ, Tsubota K, Bonasera SJ, Palmeira CM, Seidman JG, Seidman CE, Wolf NS, Kreiling JA, Sedivy JM, Murphy GF, Green RE, Garcia BA, Berger SL, Oberdoerffer P, Shankland SJ, Gladyshev VN, Ksander BR, Pfenning AR, Rajman LA, Sinclair DA
Life Science Res 8: 126132
A number of studies have revealed that exosomes can regulate the function of target cells by secreting their contents into the TME, using crosstalk, and/or influencing major tumor-related pathways, including EMT, CSCs, angiogenesis, and metastasis involving several cell types (Wu et al., 2017)
SRS 16-86, a novel ferroptosis inhibitor with high stability in plasma and liver, improves locomotor function by enhancing GPX4, GSH, and xCT levels, while reducing lipid peroxidation, gliosis, and neuronal damage in SCI models (241)
